Motor and non-motor symptoms, drugs, and their mode of action in Parkinson ’s disease (PD): a review
AbstractParkinson ’s disease is second most common neurodegenerative disorder neurological illness that primarily affects patients in their later years of life. Specific neurons in the brain begin to malfunction resulting in a loss of a substance called dopamine which is characterized by the accumulation of α-synu clein aggregates within cells, forming structures known as Lewy bodies and Lewy neurites. It is affecting more than 1% of people worldwide (aged 65 and above) and is expected to increase in prevalence by 2030. Muscle rigidity, tremor, and unresponsiveness of motion are some of the motor signs of thi s conditio...
Source: Medicinal Chemistry Research - March 7, 2024 Category: Chemistry Source Type: research
Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia
In this study, we present the case of a 71-year-old female patient with a previous diagnosis of variant HCL who experienced a severe herpes zoster infection leading to an extensive skin eruption. The patient's initial diagnosis of HCL occurred 7 years ago, and she underwent treatment with cladribine, interferon, COP (cyclophosphamide, vincristine, and prednisone), benztropine tablets + clarithromycin dispersible, and ibrutinib. Immune disorders resulting from repeated prior chemotherapy and targeted therapy may potentially precipitate herpes zoster infection. Despite an initial two-week period of unresponsiveness to antivi...
Source: Herpes - March 5, 2024 Category: Infectious Diseases Authors: Xiaowei Feng Yuchen Tao Qi Hu Yuanxia Liu Jizhang Bao Wenwen Jiang Source Type: research
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
Conclusions: These complementary analyses suggest that benztropine is used long-term in non-tardive dyskinesia drug-induced movement disorders and in tardive dyskinesia despite risks of worsening tardive dyskinesia or adverse effects.Prim Care Companion CNS Disord 2023;25(4):22m03472.Author affiliations are listed at the end of this article.PMID:37671827 | DOI:10.4088/PCC.22m03472 (Source: Primary Care)
Source: Primary Care - September 6, 2023 Category: Primary Care Authors: Craig Chepke Betsy Benning Samantha Cicero Michael Hull Erika Giraldo Jason Yeaw Katharine Coyle Eric Jen Morgan Bron Source Type: research
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
Conclusions: These complementary analyses suggest that benztropine is used long-term in non-tardive dyskinesia drug-induced movement disorders and in tardive dyskinesia despite risks of worsening tardive dyskinesia or adverse effects.Prim Care Companion CNS Disord 2023;25(4):22m03472.Author affiliations are listed at the end of this article.PMID:37671827 | DOI:10.4088/PCC.22m03472 (Source: Primary Care)
Source: Primary Care - September 6, 2023 Category: Primary Care Authors: Craig Chepke Betsy Benning Samantha Cicero Michael Hull Erika Giraldo Jason Yeaw Katharine Coyle Eric Jen Morgan Bron Source Type: research
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
Conclusions: These complementary analyses suggest that benztropine is used long-term in non-tardive dyskinesia drug-induced movement disorders and in tardive dyskinesia despite risks of worsening tardive dyskinesia or adverse effects.Prim Care Companion CNS Disord 2023;25(4):22m03472.Author affiliations are listed at the end of this article.PMID:37671827 | DOI:10.4088/PCC.22m03472 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - September 6, 2023 Category: Primary Care Authors: Craig Chepke Betsy Benning Samantha Cicero Michael Hull Erika Giraldo Jason Yeaw Katharine Coyle Eric Jen Morgan Bron Source Type: research
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
Conclusions: These complementary analyses suggest that benztropine is used long-term in non-tardive dyskinesia drug-induced movement disorders and in tardive dyskinesia despite risks of worsening tardive dyskinesia or adverse effects.Prim Care Companion CNS Disord 2023;25(4):22m03472.Author affiliations are listed at the end of this article.PMID:37671827 | DOI:10.4088/PCC.22m03472 (Source: Primary Care)
Source: Primary Care - September 6, 2023 Category: Primary Care Authors: Craig Chepke Betsy Benning Samantha Cicero Michael Hull Erika Giraldo Jason Yeaw Katharine Coyle Eric Jen Morgan Bron Source Type: research
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
Conclusions: These complementary analyses suggest that benztropine is used long-term in non-tardive dyskinesia drug-induced movement disorders and in tardive dyskinesia despite risks of worsening tardive dyskinesia or adverse effects.Prim Care Companion CNS Disord 2023;25(4):22m03472.Author affiliations are listed at the end of this article.PMID:37671827 | DOI:10.4088/PCC.22m03472 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - September 6, 2023 Category: Primary Care Authors: Craig Chepke Betsy Benning Samantha Cicero Michael Hull Erika Giraldo Jason Yeaw Katharine Coyle Eric Jen Morgan Bron Source Type: research
Case report on antipsychotic induced catatonia in an incarcerated patient
This report describes a 35-year-old incarcerated Korean-American male with a history of unspecified psychosis who presented for antipsychotic induced catatonia after administration of haloperidol decanoate intramuscular (200 mg across the span of 1 week). Neurologic workup was performed including MRI, lumbar puncture, and electroencephalography. Despite an approximate month long hospitalization, benzodiazepine challenge, benztropine trial, and amantadine adjunct, our patient continued to experience bradykinesia, waxy flexibility, and mask-like facies, and was minimally verbally responsive. Several challenges in the tre...
Source: Frontiers in Psychiatry - August 31, 2023 Category: Psychiatry Source Type: research
Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report
CONCLUSION: his case report, which describes an atypical response to discontinuing benztropine, might offer the scientific community potential clues to better understand the pathophysiology of tardive dyskinesia.PMID:37141483 (Source: WMJ)
Source: WMJ - May 4, 2023 Category: General Medicine Authors: Sharadhi Thalner Himanshu Agrawal Source Type: research
Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report
CONCLUSION: his case report, which describes an atypical response to discontinuing benztropine, might offer the scientific community potential clues to better understand the pathophysiology of tardive dyskinesia.PMID:37141483 (Source: WMJ)
Source: WMJ - May 4, 2023 Category: General Medicine Authors: Sharadhi Thalner Himanshu Agrawal Source Type: research
Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report
CONCLUSION: his case report, which describes an atypical response to discontinuing benztropine, might offer the scientific community potential clues to better understand the pathophysiology of tardive dyskinesia.PMID:37141483 (Source: WMJ)
Source: WMJ - May 4, 2023 Category: General Medicine Authors: Sharadhi Thalner Himanshu Agrawal Source Type: research
Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report
CONCLUSION: his case report, which describes an atypical response to discontinuing benztropine, might offer the scientific community potential clues to better understand the pathophysiology of tardive dyskinesia.PMID:37141483 (Source: WMJ)
Source: WMJ - May 4, 2023 Category: General Medicine Authors: Sharadhi Thalner Himanshu Agrawal Source Type: research
Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report
CONCLUSION: his case report, which describes an atypical response to discontinuing benztropine, might offer the scientific community potential clues to better understand the pathophysiology of tardive dyskinesia.PMID:37141483 (Source: WMJ)
Source: WMJ - May 4, 2023 Category: General Medicine Authors: Sharadhi Thalner Himanshu Agrawal Source Type: research
